Smith Salley & Associates raised its position in shares of Chemed Corp. (NYSE:CHE) by 3.4% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,815 shares of the company’s stock after buying an additional 60 shares during the period. Smith Salley & Associates’ holdings in Chemed Corp. were worth $247,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in the stock. Los Angeles Capital Management & Equity Research Inc. boosted its stake in Chemed Corp. by 6.6% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 5,636 shares of the company’s stock worth $763,000 after buying an additional 350 shares during the last quarter. BlackRock Inc. boosted its stake in Chemed Corp. by 90.4% in the first quarter. BlackRock Inc. now owns 1,152 shares of the company’s stock worth $156,000 after buying an additional 547 shares during the last quarter. BlackRock Group LTD boosted its stake in Chemed Corp. by 7.2% in the first quarter. BlackRock Group LTD now owns 22,610 shares of the company’s stock worth $3,062,000 after buying an additional 1,514 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Chemed Corp. by 0.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 431,220 shares of the company’s stock worth $58,409,000 after buying an additional 1,831 shares during the last quarter. Finally, C M Bidwell & Associates Ltd. acquired a new stake in Chemed Corp. during the first quarter worth about $163,000. 98.64% of the stock is owned by institutional investors.
Chemed Corp. (NYSE:CHE) traded down 0.26% during trading on Friday, reaching $139.79. The company’s stock had a trading volume of 39,717 shares. The company has a market cap of $2.26 billion, a price-to-earnings ratio of 22.17 and a beta of 1.17. The stock’s 50 day moving average is $138.63 and its 200 day moving average is $136.21. Chemed Corp. has a 12 month low of $124.77 and a 12 month high of $160.12.
Chemed Corp. (NYSE:CHE) last issued its quarterly earnings data on Monday, July 25th. The company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.08. The firm earned $290 million during the quarter, compared to analyst estimates of $393.50 million. Chemed Corp. had a return on equity of 24.12% and a net margin of 6.93%. The company’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.71 EPS. On average, equities analysts expect that Chemed Corp. will post $7.25 EPS for the current fiscal year.
CHE has been the topic of a number of recent research reports. Royal Bank Of Canada increased their target price on Chemed Corp. from $136.00 to $162.00 and gave the stock a “sector perform” rating in a research note on Wednesday, July 27th. RBC Capital Markets reiterated a “sector perform” rating and set a $162.00 target price (up previously from $136.00) on shares of Chemed Corp. in a research note on Wednesday, July 27th. Zacks Investment Research upgraded Chemed Corp. from a “hold” rating to a “buy” rating and set a $167.00 target price on the stock in a research note on Thursday, July 28th. JMP Securities reiterated a “hold” rating on shares of Chemed Corp. in a research note on Sunday, September 4th. Finally, Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $155.00 target price on shares of Chemed Corp. in a research note on Tuesday, September 27th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $161.50.
In other news, Director Donald E. Saunders sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $144.32, for a total value of $72,160.00. Following the transaction, the director now owns 10,786 shares in the company, valued at approximately $1,556,635.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Kevin J. Mcnamara sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $144.87, for a total value of $2,607,660.00. Following the completion of the transaction, the insider now owns 163,266 shares in the company, valued at approximately $23,652,345.42. The disclosure for this sale can be found here. Company insiders own 5.32% of the company’s stock.
About Chemed Corp.
Chemed Corporation operates and divests subsidiaries engaged in diverse business activities. The Company operates its business in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.